Wolff-Parkinson-White syndrome drug prophylaxis: Difference between revisions

	Wolff-Parkinson-White syndrome Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Differentiating Wolff-Parkinson-White syndrome from other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
Approach
History and Symptoms
Electrocardiogram
EKG Examples
Other Diagnostic Studies
Treatment
Risk Stratification
Cardioversion
Medical Therapy
Catheter Ablation
Prophylaxis
Consensus Statement
Case Studies
Case #1
Wolff-Parkinson-White syndrome drug prophylaxis On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Wolff-Parkinson-White syndrome drug prophylaxis
CDC onWolff-Parkinson-White syndrome drug prophylaxis
Wolff-Parkinson-White syndrome drug prophylaxis in the news
Blogs on Wolff-Parkinson-White syndrome drug prophylaxis
Directions to Hospitals Treating Deep vein thrombosis
Risk calculators and risk factors for Wolff-Parkinson-White syndrome drug prophylaxis

Revision as of 12:37, 16 September 2020

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]

Oral beta-blocker, diltiazem, and verapamil for prevention of AVRT in patients with out preexcitation in resting ECG.
Oral flecainide and propaphenone in patients with preexcitation in resting ECG that are not candidates for catheter ablation and do not have structural or ischemic heart disease

@@ Line 2: / Line 2: @@
 {{CMG}}; '''Associate Editor-In-Chief:''' {{CZ}}
 ==Drug Prophylaxis In The Patient With Proven Tachyarrhythmias==
-# Should receive prophylactic treatment if the arrhythmia is poorly tolerated.
+* Oral [[beta-blocker]], [[diltiazem]], and [[verapamil]] for prevention of [[AVRT]] in patients with out preexcitation in resting [[ECG]].
-# In Wellen's experience amiodarone is the most effective in preventing attacks of paroxysmal tachycardia in patients with WPW. Otherwise he recommends quinidine, disopyramide, procainamide or propranolol alone or in combination.
+* Oral [[flecainide]] and [[propaphenone]] in patients with preexcitation in resting [[ECG]] that are not candidates for catheter ablation and do not have structural or [[ischemic heart disease]]
-# For those patients with life-threatening rates during afib, Wellen's recommends amiodarone as prophylaxis which prolongs the AP refractory period. Quinidine is an alternative, but is less effective.
-# These patients should undergo EP studies to assess the adequacy of treatment.
-# These authors state that the refractory period of the AP can shorten in the presence of sympathetic stimulation and advocate the addition of a beta blocker.
 ==References==